About
Titles
Hospital Resident
Biography
Mahesh Krishna graduated from Rice University in 2020 with a BA in Biochemistry and Cell Biology as well as Policy Studies and won multiple awards during his time in undergraduate including recognition as an Early Career Investigator from the American Gastroenterological Association, Excellence in Academic Advising Award, Cum Laude, Distinction in Research and Creative Work, and the 2020 Award for Excellence in Medical Research from the Rice Alumni in Medicine Society. He completed his medical degree at Johns Hopkins in 2024 and was elected to Alpha Omega Alpha. He has published 14 peer-reviewed manuscripts in reputable journals such as Inflammatory Bowel Diseases, Clinical Gastroenterology and Hepatology, and Journal of Autoimmunity. Six of these publications have been as first author with his research on Lactobacillus reuteri as a potential probiotic in maternal mice to prevent inflammatory bowel disease in offspring being cited in the recent "Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease."
He is a current internal medicine resident at Yale and hopes to pursue a career as a physician-scientist.
Last Updated on October 29, 2025.
Departments & Organizations
Education & Training
- MD
- Johns Hopkins University School of Medicine (2024)
- BA
- Rice University, Biochemistry and Cell Biology, Policy Studies
Research
Overview
Mahesh Krishna is a current internal medicine resident who is interested in gastroenterology and hepatology. He wants to pursue a career as a physician-scientist who studies modifying the gut-liver axis and the immune system to treat primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD). He is currently actively involved in research projects with Dr. Assis on the impact of genetic polymorphisms in bile acid glucuronidation on cholestatic liver diseases as well as fenofibrate on PSC-IBD.
Public Health Interests
Microbiome
ORCID
0000-0001-9762-5717
Research at a Glance
Publications Timeline
A big-picture view of Mahesh Krishna's research output by year.
22Publications
244Citations
Publications
2025
Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study
Frost S, Ambastha C, Patel D, Roney A, Greb A, Rangel-Garcia M, Sauk J, Chang C, Park S, Parian A, Suchan A, Moughames E, Krishna M, Chowdhury R, Sharma S, Maas L, Ho A, Lazarev M, Limketkai B, Limsui D, Keyashian K. Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study. Inflammatory Bowel Diseases 2025, izaf170. PMID: 40971840, DOI: 10.1093/ibd/izaf170.Peer-Reviewed Original ResearchConceptsTumor necrosis factor inhibitorsAnti-drug antibodiesTherapeutic drug monitoringAnti-drug antibody developmentProactive therapeutic drug monitoringInflammatory bowel diseaseDrug monitoringRisks of anti-drug antibodiesCohort studyIncidence of anti-drug antibodiesTumor necrosis factor-alpha inhibitorsLongitudinal riskMulticenter retrospective cohort studySubtherapeutic trough levelsAssociation of potential risk factorsMulticenter cohort studyYoung adultsRetrospective cohort studyCox regression methodRoutine drug monitoringPotential risk factorsDose escalationTrough levelsFactor inhibitorsKaplan-MeierRetrospective Cohort Study on the Predictive Value of Primary Non-response to Initial Biologic for Future Biologic Use in Patients with Inflammatory Bowel Disease
Krishna M, Spartz E, Maas L, Cusumano V, Sharma S, Limketkai B, Parian A. Retrospective Cohort Study on the Predictive Value of Primary Non-response to Initial Biologic for Future Biologic Use in Patients with Inflammatory Bowel Disease. Digestive Diseases And Sciences 2025, 70: 746-753. PMID: 39755922, DOI: 10.1007/s10620-024-08816-9.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsSecondary loss of responsePrimary non-responseInflammatory bowel diseaseLoss of responseMulticenter retrospective chart review studyArmamentarium of medical therapiesCrohn's diseaseBowel diseaseNon-responsePredictive valueRetrospective chart review studyCessation of drugWeeks of treatmentRetrospective cohort studyChart review studyTreat inflammatory bowel diseaseAdverse side effectsBiologic therapySymptomatic improvementMedical therapyRate of responseTreatment optionsUnivariate analysisMedication switchIBD-unclassified
2023
Stochasticity Driven Limitations for Counseling in Autoimmune Gastrointestinal Disease
Philip A, Krishna M, Kellermayer R. Stochasticity Driven Limitations for Counseling in Autoimmune Gastrointestinal Disease. Journal Of Pediatric Gastroenterology And Nutrition 2023, 77: 695-697. PMID: 37779233, DOI: 10.1097/mpg.0000000000003955.Peer-Reviewed Original ResearchCitationsAltmetricSuperior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae
Maas L, Gao R, Cusumano V, Spartz E, Chowdhury R, Krishna M, Lazarev M, Melia J, Selaru F, Sharma S, Limketkai B, Parian A. Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae. Digestive Diseases And Sciences 2023, 68: 3994-4000. PMID: 37540392, DOI: 10.1007/s10620-023-08060-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdalimumab groupInfliximab groupClinical responsePerianal fistulasTumor necrosis factor inhibitorsConcomitant immunomodulator therapyHigher treatment persistenceEfficacy of infliximabFirst-line treatmentKaplan Meier methodMethodsA retrospective studyAssociated with higher ratesCrohn's perianal fistulasDose escalationConcomitant immunomodulatorsFistula responseImmunomodulating therapyFactor inhibitorsMeier methodTreatment persistenceSecondary endpointsClinical improvementInitial treatmentRetrospective studySuperior efficacyMachine Learning-based Characterization of Longitudinal Health Care Utilization Among Patients With Inflammatory Bowel Diseases
Limketkai B, Maas L, Krishna M, Dua A, DeDecker L, Sauk J, Parian A. Machine Learning-based Characterization of Longitudinal Health Care Utilization Among Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 2023, 30: 697-703. PMID: 37454280, PMCID: PMC11491632, DOI: 10.1093/ibd/izad127.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHealth care utilizationCare utilizationInflammatory bowel diseaseClinical encountersTargeted care coordinationUtilization patternsHealth care resource utilizationPoisson regression modelsElectronic medical recordsRetrospective studyStudy of adultsInitiation of biologic therapyCare coordinationRetrospective study of adultsBowel diseasePatient risk assessmentBiologic therapy initiationPrescription of corticosteroidsBaseline clinical characteristicsBaseline clinical factorsTelephone encountersInflammatory bowel disease patientsPoisson regressionResource utilizationFrequency of clinical encountersSu1813 INCIDENCE OF ANTI-DRUG ANTIBODY DEVELOPMENT IN OLDER ADULTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH TUMOR NECROSIS FACTOR ALPHA INHBITORS: A LARGE MULTICENTER COHORT STUDY
Frost S, Sauk J, Patel D, Roney A, Park S, Rangel-Garcia M, Chang C, Parian A, Suchan A, Moughames E, Krishna M, Lazarev M, Chowdhury R, Sharma S, Maas L, Ho A, Limketkai B, Limsui D, Keyashian K. Su1813 INCIDENCE OF ANTI-DRUG ANTIBODY DEVELOPMENT IN OLDER ADULTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH TUMOR NECROSIS FACTOR ALPHA INHBITORS: A LARGE MULTICENTER COHORT STUDY. Gastroenterology 2023, 164: s-694-s-695. DOI: 10.1016/s0016-5085(23)02611-2.Peer-Reviewed Original ResearchTu1801 LOW RATES OF SUCCESSFUL TOFACITINIB DOSE DE-ESCALATION IN ULCERATIVE COLITIS: A RETROSPECTIVE STUDY
Maas L, Sharma S, Chowdhury R, Krishna M, Moughames E, Suchan A, Gonzaga E, Tsipotis E, Parian A, Lazarev M. Tu1801 LOW RATES OF SUCCESSFUL TOFACITINIB DOSE DE-ESCALATION IN ULCERATIVE COLITIS: A RETROSPECTIVE STUDY. Gastroenterology 2023, 164: s-1135. DOI: 10.1016/s0016-5085(23)03616-8.Peer-Reviewed Original ResearchLetter: fulminant‐onset complicated inflammatory bowel disease (IBD)—a unique subtype?
Szigeti R, Krishna M, Kellermayer R. Letter: fulminant‐onset complicated inflammatory bowel disease (IBD)—a unique subtype? Alimentary Pharmacology & Therapeutics 2023, 57: 1192-1193. PMID: 37094325, DOI: 10.1111/apt.17418.Peer-Reviewed Original ResearchCitations
2022
Dietary Interventions for the Treatment of Inflammatory Bowel Diseases: An Updated Systematic Review and Meta-analysis
Limketkai B, Godoy-Brewer G, Parian A, Noorian S, Krishna M, Shah N, White J, Mullin G. Dietary Interventions for the Treatment of Inflammatory Bowel Diseases: An Updated Systematic Review and Meta-analysis. Clinical Gastroenterology And Hepatology 2022, 21: 2508-2525.e10. PMID: 36470529, DOI: 10.1016/j.cgh.2022.11.026.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPartial enteral nutritionInflammatory bowel diseaseMaintenance of remissionCertainty of evidenceTreatment of inflammatory bowel diseaseSolid food dietCrohn's diseaseEnteral nutritionLow-refined carbohydrate dietBowel diseaseSystematic reviewRefined carbohydrate dietInduction of remissionAbstractText Label="Background &Carbohydrate dietRisk of relapseMeta-analysisSpecific carbohydrate dietRed meatOverall quality of evidenceQuality of evidenceCD relapseAssessment of certainty of evidenceFood dietDietary interventionS795 Predictive Value of Primary Non-Response in Initial Biologic for IBD on Future Biologics
Krishna M, Spartz E, Cusumano V, Limketkai B, Lazarev M, Parian A. S795 Predictive Value of Primary Non-Response in Initial Biologic for IBD on Future Biologics. The American Journal Of Gastroenterology 2022, 117: e566-e567. DOI: 10.14309/01.ajg.0000859820.47182.15.Peer-Reviewed Original Research